Puertas Maria C, Bailón Lucía, Urrea Víctor, García-Guerrero Maria C, Alarcón-Soto Yovaninna, Rivero Angel, Mothe Beatriz, Moltó José, Martinez-Picado Javier
IrsiCaixa, Badalona, Barcelona, Spain.
Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.
PLoS Pathog. 2025 Sep 11;21(9):e1013466. doi: 10.1371/journal.ppat.1013466. eCollection 2025 Sep.
Despite its efficacy, antiretroviral therapy (ART) is not curative, and HIV-1 rebound occurs whenever treatment is interrupted. The viral reservoir in latently infected cells is the source of the infection resurgence, making it crucial to understand when and how this reservoir is established so that it can be targeted more effectively. In this study, we evaluated the decay dynamics of proviral DNA in 40 ART-naive people initiating dolutegravir-based treatment and compared these dynamics to the decay kinetics of inducible proviruses, as measured using the VIP-SPOT assay. Intensive sampling during the first month, followed by regular sampling up to 48 weeks, enabled us to outline the biphasic decay dynamics of different fractions of the viral reservoir. Our results show that the first decay phase of inducible proviruses is significantly faster than that of total HIV-1 DNA (2.6 days versus 5.1 weeks), indicating that selective pressure on this specific fraction of proviruses is particularly effective during the first days after ART initiation. These findings suggest that therapeutic interventions aimed at impacting the viral reservoir by boosting the immune response targeting the inducible fraction should be implemented at the time of, or immediately before, treatment initiation.
尽管抗逆转录病毒疗法(ART)具有疗效,但它并不能治愈疾病,而且每当治疗中断时,HIV-1就会反弹。潜伏感染细胞中的病毒储存库是感染复发的源头,因此了解该储存库何时以及如何建立至关重要,以便能更有效地对其进行靶向治疗。在本研究中,我们评估了40名初治患者在开始基于度鲁特韦的治疗时前病毒DNA的衰减动态,并将这些动态与通过VIP-SPOT检测法测量的可诱导前病毒的衰减动力学进行了比较。在第一个月进行密集采样,随后定期采样直至48周,这使我们能够勾勒出病毒储存库不同部分的双相衰减动态。我们的结果表明,可诱导前病毒的第一个衰减阶段明显快于总HIV-1 DNA的衰减阶段(2.6天对5.1周),这表明在ART开始后的头几天,对这一特定部分前病毒的选择压力尤为有效。这些发现表明,旨在通过增强针对可诱导部分的免疫反应来影响病毒储存库的治疗干预措施应在治疗开始时或即将开始治疗之前实施。